TC
CRVS icon

Truvestments Capital’s Corvus Pharmaceuticals CRVS Stock Holding History

Truvestments Capital’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$150K Hold
10,257
– – 0.03% 335
2025
Q4 		$79K Buy
10,257
+4,744
+86% +$37.4K 0.01% 380
2025
Q3 		$40.6K Buy
5,513
+738
+15% +$3.78K 0.01% 475
2025
Q2 		$19.1K Buy
+4,775
New +$17.4K ﹤0.01% 544

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Truvestments Capital's CRVS Position: Q1 2026 in Review

Truvestments Capital held its Corvus Pharmaceuticals (CRVS) position steady in Q1 2026 at 10,257 shares worth $150K. The position accounts for 0.03% of the portfolio, ranked #335.

Truvestments Capital first reported a position in CRVS in Q2 2025 and has held it in 4 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Truvestments Capital held 10,257 shares of Corvus Pharmaceuticals worth $150K as of Q1 2026.
  • Truvestments Capital left its Corvus Pharmaceuticals share count unchanged in Q1 2026.
  • Corvus Pharmaceuticals made up 0.03% of Truvestments Capital's portfolio in Q1 2026, its #335 holding.
  • Truvestments Capital first reported a position in Corvus Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Truvestments Capital's 13F filing for Q1 2026, filed 13 May 2026.